应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01548 金斯瑞生物科技
未开盘 03-30 16:08:20
11.000
-0.100
-0.90%
最高
11.060
最低
10.760
成交量
663.88万
今开
10.960
昨收
11.100
日振幅
2.70%
总市值
240.57亿
流通市值
240.57亿
总股本
21.87亿
成交额
7,249万
换手率
0.30%
流通股本
21.87亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
金斯瑞(01548)2025年报观:三大业务协同增长,体系化竞争彰显长期价值
智通财经 · 03-18
金斯瑞(01548)2025年报观:三大业务协同增长,体系化竞争彰显长期价值
大和:降金斯瑞生物科技(01548)目标价至21港元 续予“买入”评级
智通财经 · 03-18
大和:降金斯瑞生物科技(01548)目标价至21港元 续予“买入”评级
异动解读 | 年度收益大增61.4%且联营公司亏损收窄,金斯瑞生物科技盘中大涨6.32%
异动解读 · 03-17
异动解读 | 年度收益大增61.4%且联营公司亏损收窄,金斯瑞生物科技盘中大涨6.32%
港股异动 | 金斯瑞生物科技(01548)涨超5% 年度收益同比增加61.4% 传奇生物亏损大幅收窄
智通财经 · 03-17
港股异动 | 金斯瑞生物科技(01548)涨超5% 年度收益同比增加61.4% 传奇生物亏损大幅收窄
金斯瑞生物科技公布强劲2025财年业绩:一体化平台战略与全球化执行驱动高质量增长
美股速递 · 03-16
金斯瑞生物科技公布强劲2025财年业绩:一体化平台战略与全球化执行驱动高质量增长
金斯瑞生物科技(01548):林慧怡已获委任为公司秘书
智通财经 · 03-15
金斯瑞生物科技(01548):林慧怡已获委任为公司秘书
金斯瑞生物科技:2025年净亏损5.32亿美元
南方财经网 · 03-15
金斯瑞生物科技:2025年净亏损5.32亿美元
金斯瑞生物科技(01548)2025年股本变动:行使股份期权与限制性股份单位,股本增至2,185千美元
公告速递 · 03-15
金斯瑞生物科技(01548)2025年股本变动:行使股份期权与限制性股份单位,股本增至2,185千美元
【新股IPO】据报传奇生物计划今年在香港上市 集资3亿至4亿美元
金吾财讯 · 03-12
【新股IPO】据报传奇生物计划今年在香港上市 集资3亿至4亿美元
大摩:降金斯瑞生物科技(01548)目标价至16.5港元 维持“增持”评级
智通财经 · 03-11
大摩:降金斯瑞生物科技(01548)目标价至16.5港元 维持“增持”评级
金斯瑞生物科技(01548)发盈警,预期2025年度亏损约5.06亿美元至5.86亿美元 同比盈转亏
智通财经 · 03-10
金斯瑞生物科技(01548)发盈警,预期2025年度亏损约5.06亿美元至5.86亿美元 同比盈转亏
金斯瑞生物科技2025财年许可收益最高2.99亿美元,经调整净利润最高2.42亿美元
公告速递 · 03-10
金斯瑞生物科技2025财年许可收益最高2.99亿美元,经调整净利润最高2.42亿美元
每日卖空追踪 | 金斯瑞生物科技 03月09日卖空量成交60.2万股,卖空比例为5.84%
市场透视 · 03-09
每日卖空追踪 | 金斯瑞生物科技 03月09日卖空量成交60.2万股,卖空比例为5.84%
金斯瑞生物科技(01548.HK)拟3月15日举行董事会会议批准年度业绩
中金财经 · 03-04
金斯瑞生物科技(01548.HK)拟3月15日举行董事会会议批准年度业绩
每日卖空追踪 | 金斯瑞生物科技 03月04日卖空量成交115.8万股,卖空比例为10.15%
市场透视 · 03-04
每日卖空追踪 | 金斯瑞生物科技 03月04日卖空量成交115.8万股,卖空比例为10.15%
金斯瑞生物科技03月04日遭主力抛售111.7万元
市场透视 · 03-04
金斯瑞生物科技03月04日遭主力抛售111.7万元
金斯瑞生物(01548)更新2026年2月股份变动月报表,股本维持稳定
公告速递 · 03-03
金斯瑞生物(01548)更新2026年2月股份变动月报表,股本维持稳定
每日卖空追踪 | 金斯瑞生物科技 02月27日卖空量成交106万股,卖空比例为8.66%
市场透视 · 02-27
每日卖空追踪 | 金斯瑞生物科技 02月27日卖空量成交106万股,卖空比例为8.66%
每日卖空追踪 | 金斯瑞生物科技 02月25日卖空量成交44.6万股,卖空比例为13.02%
市场透视 · 02-25
每日卖空追踪 | 金斯瑞生物科技 02月25日卖空量成交44.6万股,卖空比例为13.02%
金斯瑞生物科技02月24日主力净流出43.5万元 散户资金买入
市场透视 · 02-24
金斯瑞生物科技02月24日主力净流出43.5万元 散户资金买入
加载更多
公司概况
公司名称:
金斯瑞生物科技
所属市场:
SEHK
上市日期:
--
主营业务:
金斯瑞生物科技股份有限公司是一家主要从事生产及销售生命科学研究产品及服务的投资控股公司。该公司通过五个分部开展业务。生命科学服务及产品分部提供全面的研究服务及产品。生物制剂开发服务分部以一个综合平台提供全面服务,旨在帮助生物制药及生物技术公司加快治疗性抗体及基因、细胞疗法产品的开发。工业合成生物产品分部通过使用基因工程建构非病源微生物株,提供工业酶开发和生产。细胞疗法分部发现和开发用于治疗液体及固体肿瘤的CAR-T疗法。经营管理分部主要为其他分部提供共享服务。该公司主要在中国国内和海外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"01548","market":"HK","secType":"STK","nameCN":"金斯瑞生物科技","latestPrice":11,"timestamp":1774858100003,"preClose":11.1,"halted":0,"volume":6638830,"delay":0,"changeRate":-0.009009009009008978,"floatShares":2187000000,"shares":2187000000,"eps":-1.9262719037020783,"marketStatus":"未开盘","change":-0.1,"latestTime":"03-30 16:08:20","open":10.96,"high":11.06,"low":10.76,"amount":72489451,"amplitude":0.027027,"askPrice":11,"askSize":92000,"bidPrice":10.97,"bidSize":22000,"shortable":3,"etf":0,"ttmEps":-1.9262719037020783,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774920600000},"marketStatusCode":0,"adr":0,"listingDate":1451404800000,"exchange":"SEHK","adjPreClose":11.1,"openAndCloseTimeList":[[1774834200000,1774843200000],[1774846800000,1774857600000]],"volumeRatio":0.853594,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01548","defaultTab":"news","newsList":[{"id":"2620173236","title":"金斯瑞(01548)2025年报观:三大业务协同增长,体系化竞争彰显长期价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2620173236","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620173236?lang=zh_cn&edition=full","pubTime":"2026-03-18 17:00","pubTimestamp":1773824401,"startTime":"0","endTime":"0","summary":"3月15日,金斯瑞公布了2025年全年业绩。财报显示,2025年,公司持续经营业务实现收益约9.6亿美元,同比大幅增长61.4%。百斯杰的核心业务稳中有进,为中长期增长蓄力。年内,该公司持续推进多平台协同发展,积极开拓新增长曲线,形成了“基因至蛋白一体化平台”,以体系化竞争优势持续领跑。2025年,百斯杰收入约为5800万美元,同比增长7.9%;经调整毛利约为2300万美元,增速超越行业平均增速5%,迎来关键增长拐点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415428.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","HK0000320223.HKD","HK0000320264.USD","HK0000306685.HKD","01548","BK1583","BK1576","BK1141"],"gpt_icon":0},{"id":"2620825832","title":"大和:降金斯瑞生物科技(01548)目标价至21港元 续予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2620825832","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620825832?lang=zh_cn&edition=full","pubTime":"2026-03-18 14:00","pubTimestamp":1773813650,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,大和发布研报称,金斯瑞生物科技去年业绩符合预期,销售额同比增61%至9.6亿美元,符合该行预测的9.61亿美元;经调整净利润升285%至2.3亿美元。该行维持金斯瑞生物科技“买入”评级,目标价由26港元下调至21港元,以反映对其联营公司传奇生物的较低估值。至于今年指引,金斯瑞生物科技料Genscript Life Science收入同比增长15至18%,经调整毛行率约为52%; 经调整经营溢利约19%。另外,该行下调公司2026至27年的每股盈测10%及1%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01548"],"gpt_icon":0},{"id":"1177805767","title":"异动解读 | 年度收益大增61.4%且联营公司亏损收窄,金斯瑞生物科技盘中大涨6.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177805767","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177805767?lang=zh_cn&edition=full","pubTime":"2026-03-17 11:25","pubTimestamp":1773717902,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技今日盘中大涨6.32%,引起了市场的广泛关注。消息面上,公司发布了截至2025年12月31日止的年度业绩报告,期内取得收益9.6亿美元,同比大幅增加61.4%,主要归因于许可收益的大幅增长以及其他业务的稳健表现。收益的强劲增长带动公司毛利显著上升,持续经营业务的毛利约为5.53亿美元,较上期增长103.3%。同时,传奇生物的亏损大幅收窄至0.33亿美元,并有望在2026年实现盈利。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01548"],"gpt_icon":0},{"id":"2620412370","title":"港股异动 | 金斯瑞生物科技(01548)涨超5% 年度收益同比增加61.4% 传奇生物亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2620412370","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620412370?lang=zh_cn&edition=full","pubTime":"2026-03-17 11:15","pubTimestamp":1773717332,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,金斯瑞生物科技涨超5%,截至发稿,涨3.24%,报66.95港元,成交额6281.35万港元。消息面上,3月15日,金斯瑞生物科技发布截至2025年12月31日止年度业绩,该集团期内取得收益9.6亿美元,同比增加61.4%;母公司拥有人应占亏损5.33亿美元,同比盈转亏;每股基本亏损24.58美分。华泰证券指出,金斯瑞生物科技2025年业绩符合预期,各主要业务板块展现稳健增长或扭亏态势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LEGN","BK4139","HK0000306701.USD","VXUS","HK0000320223.HKD","HK0000306685.HKD","HK0000320264.USD","01548","BK4588","BK4505","BK4585","BK1141","BK1583","BK1576"],"gpt_icon":0},{"id":"1167834481","title":"金斯瑞生物科技公布强劲2025财年业绩:一体化平台战略与全球化执行驱动高质量增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1167834481","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167834481?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:15","pubTimestamp":1773656134,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技公司公布了其2025财年的强劲业绩。报告显示,公司通过其一体化平台战略和高效的全球化执行能力,成功驱动了高质量的业务增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548","HK0000320264.USD","HK0000306701.USD","HK0000306685.HKD","BK1583","BK1576","BK1141","HK0000320223.HKD"],"gpt_icon":0},{"id":"2619106931","title":"金斯瑞生物科技(01548):林慧怡已获委任为公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2619106931","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619106931?lang=zh_cn&edition=full","pubTime":"2026-03-15 19:31","pubTimestamp":1773574297,"startTime":"0","endTime":"0","summary":"智通财经APP讯,金斯瑞生物科技(01548)发布公告,黄慧玲女士(黄女士)已辞任本公司公司秘书及根据香港法例第 622章《公司条例》第16部项下的本公司授权代表 (公司条例项下的授权代表),自 2026年3月15日起生效。林慧怡女士(林女士)已获委任为公司秘书及公司条例项下的授权代表,自2026年3月15日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","HK0000320264.USD","BK1583","01548","HK0000320223.HKD","HK0000306701.USD","BK1141","HK0000306685.HKD"],"gpt_icon":0},{"id":"2619106876","title":"金斯瑞生物科技:2025年净亏损5.32亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2619106876","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619106876?lang=zh_cn&edition=full","pubTime":"2026-03-15 19:14","pubTimestamp":1773573242,"startTime":"0","endTime":"0","summary":"南财智讯3月15日电,金斯瑞生物科技(01548.HK)公告,截至2025年12月31日止年度,公司总收益为9.60亿美元,同比增长61.4%;年内亏损为5.32亿美元;每股基本亏损为0.25美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603153672410538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01548","HK0000306701.USD","HK0000320223.HKD","HK0000306685.HKD","HK0000320264.USD","BK1141","BK1583","BK1576"],"gpt_icon":0},{"id":"1145014066","title":"金斯瑞生物科技(01548)2025年股本变动:行使股份期权与限制性股份单位,股本增至2,185千美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145014066","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145014066?lang=zh_cn&edition=full","pubTime":"2026-03-15 19:11","pubTimestamp":1773573091,"startTime":"0","endTime":"0","summary":"于2024年及2025年12月31日,金斯瑞生物科技(01548)的授权股本金额均为5,000千美元。2025年1月1日,公司已发行股份数目为2,142,296,633股,对应股本2,142千美元。报告期内,因行使股份期权及限制性股份单位,新增42,408,537股,股本相应增至2,185千美元。至2025年12月31日,公司已发行股份总数增至2,184,705,170股,未见其他回购记录或关于其他激励计划的信息。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"gpt_icon":0},{"id":"2618718200","title":"【新股IPO】据报传奇生物计划今年在香港上市 集资3亿至4亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618718200","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618718200?lang=zh_cn&edition=full","pubTime":"2026-03-12 17:07","pubTimestamp":1773306468,"startTime":"0","endTime":"0","summary":"金吾财讯 | 有报道引述消息人士称,金斯瑞生物科技(01548)联营公司传奇生物计划今年在香港上市,集资3亿至4亿美元。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/MjI2MDllNmU0MDE4OTQyNzM4NTczYjJhMDY4OTU0MjU2ODIwNTMx.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MjI2MDllNmU0MDE4OTQyNzM4NTczYjJhMDY4OTU0MjU2ODIwNTMx.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976400","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","BK1583","BK4588","HK0000320223.HKD","BK4585","01548","HK0000306685.HKD","BK1141","HK0000320264.USD","HK0000306701.USD","LEGN","BK4505","BK4139"],"gpt_icon":0},{"id":"2618911602","title":"大摩:降金斯瑞生物科技(01548)目标价至16.5港元 维持“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2618911602","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618911602?lang=zh_cn&edition=full","pubTime":"2026-03-11 15:40","pubTimestamp":1773214838,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,摩根士丹利发布研报称,金斯瑞生物科技(01548)发盈警后,已将其2026至30年的盈测下调1%至13%,相应目标价由18.3港元下调至16.5港元,维持“增持”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01548"],"gpt_icon":0},{"id":"2618951830","title":"金斯瑞生物科技(01548)发盈警,预期2025年度亏损约5.06亿美元至5.86亿美元 同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2618951830","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618951830?lang=zh_cn&edition=full","pubTime":"2026-03-10 22:34","pubTimestamp":1773153297,"startTime":"0","endTime":"0","summary":"于本公告日期,公司预计将在报告期的年度业绩中取得减值亏损约3.78亿美元至4.38亿美元。集团预计于报告期内将取得亏损约5.06亿美元至5.86亿美元,而上期则取得利润约29亿美元。报告期内传奇的经调整净亏损由上期的1.89亿美元收窄至报告期的3310万美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"金斯瑞生物科技(01548)发盈警,预期2025年度亏损约5.06亿美元至5.86亿美元 同比盈转亏","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01548","HK0000320223.HKD","BK1576","BK1141","HK0000306701.USD","HK0000306685.HKD","BK1583","HK0000320264.USD"],"gpt_icon":0},{"id":"1135386928","title":"金斯瑞生物科技2025财年许可收益最高2.99亿美元,经调整净利润最高2.42亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135386928","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135386928?lang=zh_cn&edition=full","pubTime":"2026-03-10 22:34","pubTimestamp":1773153258,"startTime":"0","endTime":"0","summary":"本期信息\n根据金斯瑞生物科技(股票代码:01548)公告,2025财年(截至2025年12月31日止年度)经调整净利润预计约2.07亿美元至2.42亿美元,相较上期约0.60亿美元增长246.5%至304.3%。公告显示,本期盈利能力的增长主要得益于许可收益的显著提升。公司预计本期许可收益约2.56亿美元至2.99亿美元,上期为约0.024亿美元。\n业务分项\n公告指出,上述许可收益的增长主要来自礼新医药科技有限公司带来的分许可收益。管理层认为,此项收入迅速扩大是推动公司整体盈利能力提升的重要动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"gpt_icon":0},{"id":"2618644988","title":"每日卖空追踪 | 金斯瑞生物科技 03月09日卖空量成交60.2万股,卖空比例为5.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618644988","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618644988?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:30","pubTimestamp":1773045023,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技北京时间03月09日,涨2.19%,卖空量成交60.2万股,较上一交易日减少64.34%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163248a45ae696&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163248a45ae696&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01548","HK0000320223.HKD","BK1583","BK1141","BK1576","HK0000320264.USD","HK0000306701.USD","HK0000306685.HKD"],"gpt_icon":0},{"id":"2616153350","title":"金斯瑞生物科技(01548.HK)拟3月15日举行董事会会议批准年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2616153350","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616153350?lang=zh_cn&edition=full","pubTime":"2026-03-04 17:07","pubTimestamp":1772615229,"startTime":"0","endTime":"0","summary":"格隆汇3月4日丨金斯瑞生物科技(01548.HK)公布,董事会会议将于2026年3月15日(星期日)举行,藉以(其中包括)考虑及批准本公司及其附属公司截至2025年12月31止年度的年度业绩及其发布,并考虑派发年度股息(如有)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260304/32044418.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01548","HK0000320223.HKD","BK1583","BK1141","BK1576","HK0000320264.USD","HK0000306701.USD","HK0000306685.HKD"],"gpt_icon":0},{"id":"2616551095","title":"每日卖空追踪 | 金斯瑞生物科技 03月04日卖空量成交115.8万股,卖空比例为10.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616551095","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616551095?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:30","pubTimestamp":1772613022,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技北京时间03月04日,跌1.72%,卖空量成交115.8万股,较上一交易日减少42.96%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163255a6a14d42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163255a6a14d42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1583","HK0000320264.USD","HK0000306701.USD","HK0000320223.HKD","HK0000306685.HKD","BK1141","01548"],"gpt_icon":0},{"id":"2616551059","title":"金斯瑞生物科技03月04日遭主力抛售111.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616551059","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616551059?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:16","pubTimestamp":1772612168,"startTime":"0","endTime":"0","summary":"03月04日, 金斯瑞生物科技股价跌1.72%,报收10.84元,成交金额1.2亿元,换手率0.52%,振幅4.08%,量比1.22。金斯瑞生物科技今日主力资金净流出111.7万元,连续7日净流出,上一交易日主力净流出367.8万元。该股近5个交易日下跌11.94%,主力资金累计净流出1321.8万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流入3160.1万元,其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304162217a6a1418b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304162217a6a1418b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1141","BK1583","01548","HK0000306701.USD","HK0000320264.USD","HK0000320223.HKD","HK0000306685.HKD"],"gpt_icon":0},{"id":"1199054008","title":"金斯瑞生物(01548)更新2026年2月股份变动月报表,股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1199054008","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199054008?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:32","pubTimestamp":1772526760,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技股份有限公司(01548)于2026年3月3日发布截至2026年2月28日的股份变动月报表。公告显示,截至本月底,公司注册股本维持为5,000,000美元(对应5,000,000,000股,每股面值0.001美元),与上月底相同。\n报告期内,公司已发行股份总数仍为2,186,518,520股,与上月底相比没有新增发行、购回、注销或库藏股变化。公司现行股份期权计划未导致任何新股发行或库藏股转让,期末累计可行使期权数为25,641,294份。\n公司强调已符合适用的公众持股量要求,并重申在运营及资本结构上继续遵循香港联合交易所有限公司上市规则。公告由董事孟建革签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"gpt_icon":0},{"id":"2614863989","title":"每日卖空追踪 | 金斯瑞生物科技 02月27日卖空量成交106万股,卖空比例为8.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614863989","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614863989?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:30","pubTimestamp":1772181023,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技北京时间02月27日,涨0.59%,卖空量成交106万股,较上一交易日减少49.57%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227163251a436773f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227163251a436773f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","HK0000306685.HKD","01548","HK0000320264.USD","HK0000320223.HKD","HK0000306701.USD","BK1576","BK1141"],"gpt_icon":0},{"id":"2614705020","title":"每日卖空追踪 | 金斯瑞生物科技 02月25日卖空量成交44.6万股,卖空比例为13.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614705020","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614705020?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:30","pubTimestamp":1772008225,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技北京时间02月25日,股价较前一交易日持平,卖空量成交44.6万股,较上一交易日减少85.5%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225163254a71d591a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225163254a71d591a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","HK0000306701.USD","01548","HK0000306685.HKD","BK1583","BK1576","HK0000320223.HKD","HK0000320264.USD"],"gpt_icon":0},{"id":"2614735307","title":"金斯瑞生物科技02月24日主力净流出43.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2614735307","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614735307?lang=zh_cn&edition=full","pubTime":"2026-02-24 16:15","pubTimestamp":1771920951,"startTime":"0","endTime":"0","summary":"02月24日, 金斯瑞生物科技股价跌0.65%,报收12.23元,成交金额1.5亿元,换手率0.55%,振幅4.31%,量比1.56。金斯瑞生物科技今日主力资金净流出43.5万元,上一交易日主力净流出0万元。该股近5个交易日下跌0.89%,主力资金累计净流入299.3万元;近20日主力资金累计净流入5603.4万元,其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224162034a7190c7f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224162034a7190c7f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","HK0000320223.HKD","01548","HK0000320264.USD","HK0000306685.HKD","HK0000306701.USD","BK1583","BK1576"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genscript.com","stockEarnings":[{"period":"1week","weight":0.0377},{"period":"1month","weight":-0.0787},{"period":"3month","weight":-0.1165},{"period":"6month","weight":-0.3421},{"period":"1year","weight":-0.1325},{"period":"ytd","weight":-0.1143}],"compareEarnings":[{"period":"1week","weight":0.0151},{"period":"1month","weight":-0.0706},{"period":"3month","weight":-0.0427},{"period":"6month","weight":-0.0784},{"period":"1year","weight":0.0565},{"period":"ytd","weight":-0.0343}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"金斯瑞生物科技股份有限公司是一家主要从事生产及销售生命科学研究产品及服务的投资控股公司。该公司通过五个分部开展业务。生命科学服务及产品分部提供全面的研究服务及产品。生物制剂开发服务分部以一个综合平台提供全面服务,旨在帮助生物制药及生物技术公司加快治疗性抗体及基因、细胞疗法产品的开发。工业合成生物产品分部通过使用基因工程建构非病源微生物株,提供工业酶开发和生产。细胞疗法分部发现和开发用于治疗液体及固体肿瘤的CAR-T疗法。经营管理分部主要为其他分部提供共享服务。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.000341},{"month":2,"riseRate":0.545455,"avgChangeRate":0.075475},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.060195},{"month":4,"riseRate":0.5,"avgChangeRate":0.038375},{"month":5,"riseRate":0.5,"avgChangeRate":0.068155},{"month":6,"riseRate":0.6,"avgChangeRate":0.044564},{"month":7,"riseRate":0.6,"avgChangeRate":0.075818},{"month":8,"riseRate":0.4,"avgChangeRate":0.101263},{"month":9,"riseRate":0.4,"avgChangeRate":-0.071937},{"month":10,"riseRate":0.6,"avgChangeRate":0.095918},{"month":11,"riseRate":0.6,"avgChangeRate":0.045101},{"month":12,"riseRate":0.3,"avgChangeRate":0.042047}],"exchange":"SEHK","name":"金斯瑞生物科技","nameEN":"GENSCRIPT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金斯瑞生物科技,01548,金斯瑞生物科技股票,金斯瑞生物科技股票老虎,金斯瑞生物科技股票老虎国际,金斯瑞生物科技行情,金斯瑞生物科技股票行情,金斯瑞生物科技股价,金斯瑞生物科技股市,金斯瑞生物科技股票价格,金斯瑞生物科技股票交易,金斯瑞生物科技股票购买,金斯瑞生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}